# A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

> **NCT06829459** · PHASE3 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Glumetinib
- **DRUG:** Osimertinib mesylate
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin or carboplatin

## Key facts

- **NCT ID:** NCT06829459
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2028-02-15
- **Final completion:** 2029-02-15
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829459, "A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06829459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*